Maitake Beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse

Experimental Biology and Medicine

Volumn 234, Issue 3, 2009, Pages 342-353

  Lin, Hong ^a   De Stanchina, Elisa D ^b   Zhou, Xi Kathy ^c   She, Yuhong ^b   Hoang, Danthanh ^c   Cheung, Sandy W ^a   Cassileth, Barrie ^b   Cunningham Rundles, Susanna ^a,d  

^a Department of Pediatrics   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Cornell University Weill Medical College ^*  (United States)

Author keywords

Beta glucan; Cord blood; Hematopoiesis; Progenitor cell; Stem cell; Transplantation

Indexed keywords

BETA GLUCAN; CD33 ANTIGEN; CD38 ANTIGEN; DECTIN 1; DOXORUBICIN; MAITAKE BETA GLUCAN; UNCLASSIFIED DRUG; CD34 ANTIGEN; MEMBRANE PROTEIN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD34 SELECTION; CELL EXPANSION; CELL HOMING; COLONY FORMING UNIT GM; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INFANT; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NORMAL HUMAN; PROTEIN EXPRESSION; SCID MOUSE; ANIMAL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FETUS BLOOD; GRIFOLA; METABOLISM; MOUSE MUTANT;

BASIDIOMYCOTA; FUNGI; GRIFOLA FRONDOSA; HORDEUM; LAKE VICTORIA MARBURGVIRUS; MAMMALIA; MUS;

ANIMALS; ANTIGENS, CD34; BETA-GLUCANS; CELL MOVEMENT; CELL PROLIFERATION; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; GRIFOLA; HEMATOPOIETIC STEM CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NERVE TISSUE PROTEINS;

EID: 63349085393     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0807-RM-226     Document Type: Article

References (70)

1. Brown GD, Gordon S. Immune recognition. A new receptor for betaglucans. Nature 413:36-37, 2001.[Medline]
2. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 197:1119-1124, 2003.[Abstract/Free Full Text]
3. Willment JA, Gordon S, Brown GD. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem 276:43818-43823, 2001.[Abstract/Free Full Text]
4. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6:67-78, 2008.[CrossRef][Medline]
5. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156:1235-1246, 1996.[Abstract]
6. Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, Li B, Ratajczak J, Ratajczak MZ, Yan J. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 107: 835-840, 2006.[Abstract/Free Full Text]
7. Harada T, Kawaminami H, Miura NN, Adachi Y, Nakajima M, Yadomae T, Ohno N. Mechanism of enhanced hematopoietic response by soluble beta-glucan SCG in cyclophosphamide-treated mice. Microbiol Immunol 50:687-700, 2006.[Medline]
8. Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham-Rundles S. Maitake beta-glucan MD- fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol 4:91-99, 2004.[CrossRef] [Medline]
9. Hashimoto K, Suzuki I, Ohsawa M, Oikawa S, Yadomae T. Enhancement of hematopoietic response of mice by intraperitoneal administration of a beta-glucan, SSG, obtained from Sclerotinia sclerotiorum. J Pharmacobiodyn 13:512-517, 1990.[Medline]
10. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D. In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp Hematol 26:1247-1254, 1998.[Medline]
11. Patchen ML, MacVittie TJ, Weiss JF. Combined modality radio-protection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys 18:1069-1075, 1990.[Medline]
12. Harada T, Miura N, Adachi Y, Nakajima M, Yadomae T, Ohn N. Effect of SCG, 1, 3-beta-D- glucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice. Biol Pharm Bull 25:931-939, 2002.[CrossRef][Medline]
13. Turnbull JL, Patchen ML, Scadden DT. The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol 102:66-71, 1999.[CrossRef][Medline]
14. Patchen ML, Liang J, Vaudrain T, Martin T, Melican D, Zhong S, Stewart M, Quesenberry PJ. Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells 16:208-217, 1998. [Abstract/Free Full Text]
15. Harada T, Ohno N. Contribution of dectin-1 and granulocyte macrophage-colony stimulating factor (GM-CSF) to immunomodulating actions of beta-glucan. Int Immunopharmacol 8:556-566, 2008.[CrossRef][Medline]
16. Lin H, Cheung SW, Nesin M, Cassileth BR, Cunningham-Rundles S. Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colonystimulating factor production. Clin Vaccine Immunol 14:21-27, 2007.[Abstract/Free Full Text]
17. Gan OI, Murdoch B, Larochelle A, Dick JE. Differential maintenance of primitive human SCID- repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 90:641-650, 1997.[Abstract/Free Full Text]
18. Ballen KK. New trends in umbilical cord blood transplantation. Blood 105:3786-3792, 2005. [Abstract/Free Full Text]
19. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 3:526-532, 2003.[CrossRef][Medline]
20. Wagner JE. Umbilical cord transplantation. Leukemia 12 Suppl 1:S30-32, 1998.[Medline]
21. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 23:7210-7222, 2004.[CrossRef][Medline]
22. Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 100:645-650, 2003. [Abstract/Free Full Text]
23. Rice AM, Wood JA, Milross CG, Collins CJ, McCarthy NF, Vowels MR. Conditions that enable human hematopoietic stem cell engraftment in all NOD-SCID mice. Transplantation 69:927-935, 2000.[Medline]
24. Lowry PA, Shultz LD, Greiner DL, Hesselton RM, Kittler EL, Tiarks CY, Rao SS, Reilly J, Leif JH, Ramshaw H, Stewart FM, Quesenberry PJ. Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol Blood Marrow Transplant 2:15-23, 1996.[Medline]
25. Kollet O, Petit I, Kahn J, Samira S, Dar A, Peled A, Deutsch V, Gunetti M, Piacibello W, Nagler A, Lapidot T. Human CD34 (+) CXCR4 (-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 100:2778-2786, 2002. [Abstract/Free Full Text]
26. Voermans C, Kooi ML, Rodenhuis S, van der Lelie H, van der Schoot CE, Gerritsen WR. In vitro migratory capacity of CD34+cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 97:799-804, 2001.[Abstract/Free Full Text]
27. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845-848, 1999. [Abstract/Free Full Text]
28. Yao CL, Feng YH, Lin XZ, Chu IM, Hsieh TB, Hwang SM. Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133 (+) cells. Stem Cells Dev 15:70-78, 2006.[CrossRef][Medline]
29. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 8:146-154, 2001.[CrossRef][Medline]
30. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 13:444-453, 2007.[CrossRef][Medline]
31. Tanavde VM, Malehorn MT, Lumkul R, Gao Z, Wingard J, Garrett ES, Civin CI. Human stemprogenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. Exp Hematol 30:816-823, 2002.[CrossRef][Medline]
32. Levac K, Karanu F, Bhatia M. Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo. Haematologica 90:166-172, 2005.[Abstract/Free Full Text]
33. Li K, Chuen CK, Lee SM, Law P, Fok TF, Ng PC, Li CK, Wong D, Merzouk A, Salari H, Gu GJ, Yuen PM. Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice. Stem Cells 24:55-64, 2006. [Abstract/Free Full Text]
34. van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood 94:3055-3061, 1999.[Abstract/Free Full Text]
35. Cohen J. 1988 Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Mahwah, New Jersey: Lawrence Erlbaum Associates, 1988.
36. Dorrell C, Gan OI, Pereira DS, Hawley RG, Dick JE. Expansion of human cord blood CD34 (+) CD38 (-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood 95:102-110, 2000.[Abstract/Free Full Text]
37. Vanheusden K, Van Coppernolle S, De Smedt M, Plum J, Vandekerckhove B. In vitro expanded cells contributing to rapid severe combined immunodeficient repopulation activity are CD34+38- 33+90+45RA. Stem Cells 25:107-114, 2007.[Abstract/Free Full Text]
38. Forraz N, Pettengell R, McGuckin CP. Characterization of a lineage-negative stem-progenitor cell population optimized for ex vivo expansion and enriched for LTC-IC. Stem Cells 22:100-108, 2004.[Abstract/Free Full Text]
39. Peled T, Mandel J, Goudsmid RN, Landor C, Hasson N, Harati D, Austin M, Hasson A, Fibach E, Shpall EJ, Nagler A. Preclinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylene-pentamine. Cytotherapy 6:344-355, 2004.[CrossRef][Medline]
40. Kerre TC, De Smet G, De Smedt M, Offner F, De Bosscher J, Plum J, Vandekerckhove B. Both CD34+38+ and CD34+38- cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol 167:3692-3698, 2001. [Abstract/Free Full Text]
41. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 173:797-806, 2004. [Abstract/Free Full Text]
42. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol 137:20-35, 2007.[Medline]
43. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611-1618, 2002.[Abstract/Free Full Text]
44. Ueda T, Yoshida M, Yoshino H, Kobayashi K, Kawahata M, Ebihara Y, Ito M, Asano S, Nakahata T, Tsuji K. Hematopoietic capability of CD34+ cord blood cells: a comparison with CD34+adult bone marrow cells. Int J Hematol 73:457-462, 2001.[Medline]
45. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 8:368-376, 2002.[CrossRef][Medline]
46. Kim SK, Koh SK, Song SU, Shin SH, Choi GS, Kim WC, Lee MH, Seoh JY, Park SK, Fraser JK. Ex vivo expansion and clonality of CD34+selected cells from bone marrow and cord blood in a serum-free media. Mol Cells 14:367-373, 2002.[Medline]
47. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 9:959-963, 2003.[CrossRef][Medline]
48. McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood 106:1259-1261, 2005.[Abstract/Free Full Text]
49. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 24:287-320, 2006. [CrossRef][Medline]
50. Zhao P, Liu W, Cui Y. Rapid immune reconstitution and dendritic cell engraftment post-bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment. Exp Hematol 34:951-964, 2006.[CrossRef][Medline]
51. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A 99: 413-418, 2002.[Abstract/Free Full Text]
52. Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reca R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix met alloproteinase-9. Stem Cells 26:1231-1240, 2008. [Abstract/Free Full Text]
53. Cheung NK, Modak S. Oral (1→3), (1→4) -beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217-1223, 2002. [Abstract/Free Full Text]
54. Patchen ML, MacVittie TJ, Solberg BD, Souza LM. Survival enhancement and hemopoietic regeneration following radiation exposure: therapeutic approach using glucan and granulocyte colony-stimulating factor. Exp Hematol 18:1042-1048, 1990.[Medline]
55. Vos AP, M'Rabet L, Stahl B, Boehm G, Garssen J. Immunemodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 27:97- 140, 2007.[Medline]
56. Vetvicka V, Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin JC. Orally administered marine (1→3) -beta-D-glucan Phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol 40:291-298, 2007.[CrossRef][Medline]
57. Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, Wong SY. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol 169:3876-3882, 2002. [Abstract/Free Full Text]
58. Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, Brown GD. The human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol, 2005.
59. Borchers AT, Keen CL, Gershwin ME. Mushrooms, tumors, and immunity: an update. Exp Biol Med (Maywood) 229:393-406, 2004.[Abstract/Free Full Text]
60. Weck MM, Appel S, Werth D, Sinzger C, Bringmann A, Grunebach F, Brossart P. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 111:4264-4272, 2008. [Abstract/Free Full Text]
61. Gow NA, Netea MG, Munro CA, Ferwerda G, Bates S, Mora-Montes HM, Walker L, Jansen T, Jacobs L, Tsoni V, Brown GD, Odds FC, Van der Meer JW, Brown AJ, Kullberg BJ. Immune recognition of Candida albicans beta-glucan by Dectin-1. J Infect Dis 196:1565-1571, 2007. [CrossRef][Medline]
62. Dennehy KM, Brown GD. The role of the {beta}-glucan receptor Dectin-1 in control of fungal infection. J Leukoc Biol 82:253-258, 2007.[Abstract/Free Full Text]
63. Ishibashi K, Yoshida M, Nakabayashi I, Shinohara H, Miura NN, Adachi Y, Ohno N. Role of anti-beta-glucan antibody in host defense against fungi. FEMS Immunol Med Microbiol 44:99- 109, 2005.[CrossRef][Medline]
64. Krajicek BJ, Limper AH, Thomas CF Jr. Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr Opin Pulm Med 14:228-234, 2008.[CrossRef][Medline]
65. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (1 → 3) beta-D-glucan levels after liver transplantation. Infection 35:346-351, 2007.[CrossRef][Medline]
66. Rappleye CA, Eissenberg LG, Goldman WE. Histoplasma capsulatum alpha- (1, 3) -glucan blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A 104:1366- 1370, 2007.[Abstract/Free Full Text]
67. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639-646, 2007.[CrossRef][Medline]
68. Schwarzenberger P, Huang W, Oliver P, Byrne P, La Russa V, Zhang Z, Kolls JK. Il-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. J Immunol 167:2081-2086, 2001.[Abstract/Free Full Text]
69. Tan W, Huang W, Gu X, Zhong Q, Liu B, Schwarzenberger P. IL-17F/IL-17R interaction stimulates granulopoiesis in mice. Exp Hematol, 2008.
70. Lapidot T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci 938:83- 95, 2001.[Medline]